IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in IO Biotech, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +4 vs. Q1 2025
- Shares held
- 18.2M
- −928.9K (−4.9%) vs. Q1 2025
- Total value
- $25.3M
- +$4.44M (+21.3%) vs. Q1 2025
- New holders
- 5
- 5 more added
- Sold out
- 1
- 8 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 6,173,439 | $8.58M | 0.88% | 00.0% | Unchanged |
| Novo Holdings A/S | 3,354,449 | $4.66M | 0.33% | 00.0% | Unchanged |
| Marshall Wace, LLP | 2,105,262 | $2.93M | 0.00% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 1,972,073 | $2.74M | 0.24% | −369,034−15.8% | Reduced |
| Bank of America Corp | 1,615,074 | $2.24M | 0.00% | −36,441−2.2% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $1.20M | 0.74% | 00.0% | Unchanged |
| Morgan Stanley | 653,678 | $908.6K | 0.00% | −135,783−17.2% | Reduced |
| Landscape Capital Management, L.L.C. | 347,408 | $482.9K | 0.04% | −52,826−13.2% | Reduced |
| Dauntless Investment Group, LLC | 324,389 | $450.9K | 2.12% | −357,057−52.4% | Reduced |
| Soleus Capital Management, L.P. | 192,670 | $267.8K | 0.02% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 139,300 | $193.6K | 0.00% | +12,900+10.2% | Added |
| Sectoral Asset Management Inc | 117,691 | $163.6K | 0.11% | +22,691+23.9% | Added |
| Bridgeway Capital Management, LLC | 75,000 | $104.3K | 0.00% | 00.0% | Unchanged |
| Marex Group plc | 45,000 | $62.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 33,307 | $46.3K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 29,189 | $40.6K | 0.00% | −21,297−42.2% | Reduced |
| Citadel Advisors LLC | 28,866 | $40.1K | 0.00% | −16,689−36.6% | Reduced |
| Jane Street Group, LLC | 25,946 | $36.1K | 0.00% | +2,229+9.4% | Added |
| GWM Advisors LLC | 24,217 | $33.7K | 0.00% | +24,217 | New |
| Acadian Asset Management LLC | 23,366 | $32.0K | 0.00% | −7,492−24.3% | Reduced |
| UBS Group AG | 13,259 | $18.4K | 0.00% | +904+7.3% | Added |
| Cubist Systematic Strategies, LLC | 13,096 | $18.2K | 0.00% | +13,096 | New |
| Two Sigma Securities, LLC | 10,385 | $14.4K | 0.00% | +10,385 | New |
| Raymond James Financial Inc | 1,000 | $1.39K | 0.00% | +1,000 | New |
| Citigroup Inc | 314 | $436 | 0.00% | +314 | New |
| SBI Securities Co., Ltd. | 132 | $183 | 0.00% | +2+1.5% | Added |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −20,029−100.0% | Sold out |